Compare AQST & YDES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AQST | YDES |
|---|---|---|
| Founded | 2004 | 2013 |
| Country | United States | Taiwan |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 529.4M | 476.8M |
| IPO Year | 2007 | 2024 |
| Metric | AQST | YDES |
|---|---|---|
| Price | $4.05 | $6.12 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $9.33 | N/A |
| AVG Volume (30 Days) | ★ 2.0M | 191.8K |
| Earning Date | 11-03-2026 | 08-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $67,430,000.00 | N/A |
| Revenue This Year | $14.58 | N/A |
| Revenue Next Year | $32.78 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 0.77 | N/A |
| 52 Week Low | $2.94 | $1.70 |
| 52 Week High | $6.93 | $16.00 |
| Indicator | AQST | YDES |
|---|---|---|
| Relative Strength Index (RSI) | 38.90 | 53.75 |
| Support Level | $4.03 | $2.33 |
| Resistance Level | $4.35 | $8.89 |
| Average True Range (ATR) | 0.24 | 0.91 |
| MACD | -0.03 | -0.19 |
| Stochastic Oscillator | 29.06 | 65.11 |
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
YD Bio Ltd is a biotechnology company focused on regulated diagnostics, life science clinical services and healthcare product commercialization. Its operations include DNA methylation-based oncology testing programs in the United States under an LDT framework with CLIA-certified and CAP-accredited laboratory partners. The Company also provides life science distribution and clinical trial supply chain services, including procurement, logistics coordination and compliance-focused support for clinical development programs. It maintains ocular health product commercialization operations in the United States and consumer healthcare distribution activities in Asia. The Company operates in the United States and Taiwan, with Taiwan generating maximum revenue.